

Cereno Scientific to Participate at BIO-Europe Spring and LSX World Congress Europe 2026 on March 23-26 in Lisbon

Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced that the company will participate in the partnering conference BIO-Europe Spring 2026, March 23-25, and investment focused LSX World Congress Europe 2026, March 25-26 in Lisbon, Portugal. The events provide a strategic platform to advance discussions with potential pharmaceutical partners and engage with investors, supporting Cereno Scientific's strategy to maximize the value of its HDAC inhibitor platform and pipeline.

Cereno Scientific will participate in meetings throughout the week. Sten R. Sørensen, CEO, will also participate in a panel discussion on "Rare Diseases vs. Broad Indications: Where to Focus Early-Stage Innovation" on March 25, 2026, at 14:00-14:50 CET, at LSX World Congress Europe.

"PAH is currently one of the most active and strategically important rare disease markets. With our HDAC inhibitor platform and the strong signals of reverse vascular remodeling with CS1 from Phase IIa and preclinical data, we believe Cereno is well-positioned to advance discussions toward partnering and deals to support our growth. Our oral, once-daily small molecules are designed to target the root mechanisms of disease with the potential to modify disease progression, an approach supported by strong scientific rationale and emerging clinical data," said Sten R. Sørensen, CEO of Cereno Scientific.

Cereno Scientific's HDAC inhibitor platform is designed to address underlying disease mechanisms through epigenetic modulation. The lead candidate CS1 has demonstrated favorable safety and tolerability in a Phase IIa trial in pulmonary arterial hypertension (PAH), alongside efficacy signals including improvements in right heart function, functional class and patient quality of life, with early signs consistent with reverse vascular remodeling. CS014, a novel chemical entity HDAC inhibitor, demonstrated favorable safety and tolerability in Phase I and is advancing toward Phase II development, with an initial focus on pulmonary hypertension associated with interstitial lung disease (PH-ILD). Together, the programs represent a scalable, biology-driven approach with potential applicability across multiple cardiopulmonary and other fibrotic indications creating optionality beyond PAH and PH-ILD.

For the first time, BIO-Europe Spring and LSX Europe will take place back-to-back in Lisbon in March 2026, creating the most comprehensive meeting point for the life science innovation lifecycle. BIO-Europe Spring 2026 is recognized as Europe's premier biopharma partnering event and provides a unique platform for forging collaborations that drive innovation and accelerate the development of new treatments. LSX World Congress Europe (LSX Europe) is a leading life science fundraising and investment event, bringing innovators and investors together through strategic 1:1 meetings and targeted networking.

To book a meeting with Cereno Scientific, please contact: business.development@cerenoscientific.com, or connect with the team via the respective event partnering platforms.

For further information, please contact:

Tove Bergenholt, Head of IR & Communications
Email: tove.bergenholt@cerenoscientific.com
Phone: +46 73- 236 62 46

About Cereno Scientific AB

Cereno Scientific is pioneering treatments to enhance and extend life. The company's innovative pipeline offers disease-modifying drug candidates to empower people suffering from rare cardiovascular and pulmonary diseases to live life to the fullest.

Lead candidate CS1 is an HDAC inhibitor that works through epigenetic modulation and represents a novel therapeutic approach by targeting the root mechanisms of the pulmonary arterial hypertension (PAH). CS1 is a well-tolerated oral therapy with a favorable safety profile that has shown encouraging efficacy signals in a Phase IIa trial in patients with PAH, including improvements in right heart function, functional class and patient quality of life, with early signs consistent with reverse vascular remodeling. An Expanded Access Program enables patients that have completed the Phase IIa trial to gain access to CS1. CS014 is a new chemical entity and HDAC inhibitor with a multimodal mechanism of action as an epigenetic modulator having the potential to address the underlying pathophysiology of a range of cardiovascular and pulmonary diseases with high unmet needs. CS014 showed favorable safety and tolerability profile in Phase I, development focus for Phase II is pulmonary hypertension associated with interstitial lung disease (PH-ILD). Cereno Scientific is also pursuing a preclinical program with CS585, an oral, highly potent and selective prostacyclin (IP) receptor agonist that has demonstrated the potential to significantly improve disease mechanisms relevant to cardiovascular diseases. While CS585 has not yet been assigned a specific indication for clinical development, preclinical data indicates that it could potentially be used in rare thrombotic diseases.

The Company is headquartered in GoCo Health Innovation City, in Gothenburg, Sweden, and has a US subsidiary; Cereno Scientific Inc. based in Kendall Square, Boston, Massachusetts, US. Cereno Scientific is listed on the Nasdaq First North (CRNO B). The Company's Certified Adviser is DNB Carnegie Investment Bank AB, certifiedadviser@carnegie.se. More information can be found on www.cerenoscientific.com.